Search results for " virus"
showing 10 items of 1897 documents
Isolation and confirmation of viral nervous necrosis (VNN) disease in golden grey mullet (Liza aurata) and leaping mullet (Liza saliens) in the Irani…
2016
The present study was conducted on 428 moribund mullet fish samples to isolate and identify the causative agent of a mysterious acute mortality which recently occurred in wild mullets in Iranian waters of Caspian Sea, suspected to be due to viral nervous necrosis (VNN) disease. Disease investigation was carried out employing various diagnostic procedures such as virology, bacteriology, parasitology, haematology, histopathology, IFAT, IHC and nested RT-PCR. Brain and eye samples of affected fishes were collected in sterile conditions and then kept at -80 °C for cell culture isolation and nested RT-PCR detection of the causative agent. Other tissue samples were also collected and fixed for hi…
Inhibition of growth of measles virus by mycoplasma in cell-cultures and the restoring effect of arginine
1970
Presence of mycoplasma in MK cell cultures caused an inhibition of measles virus, as revealed by a lower plating efficiency. When arginine is supplemented to the cell-system, mycoplasma contaminated cells yield plaque titers as high as those of uncontaminated cells. The essential role of arginine for plaque formation of measles virus is suggested also by experiments in which arginine added to the agar overlay restored the plating efficiency of measles virus in cultures maintained in a minimal nutrient medium.
Treatment of chronic hepatitis C in hemodialysis patients
2008
Hepatitis C virus (HCV) infection is especially problematic in patients with end-stage renal disease (ESRD) who are undergoing hemodialysis. Rates of HCV infection are higher among hemodialysis patients than in the general population, and several routes of transmission are thought to stem from the dialysis unit. Management of chronic hepatitis C is also more complicated in hemodialysis patients because of altered pharmacokinetics and a predisposition for drug-related toxicity, particularly ribavirin-induced anemia. Clinical trials of patients with chronic hepatitis C and healthy, functioning kidney grafts are rare because of the inherent dangers of graft rejection. As a result, most studies…
Infections of susceptible and resistant mouse strains with herpes simplex virus type 1 and 2.
1980
The spread of HSV of type 1 and 2 was investigated after intraperitoneal, intraplantar and intracerebral infections of resistant (C57/bl) and susceptible (NMRI) mice. The virus spreads after i.p. infection to the spleen and the liver to the same extent in both strains of mice. However, virus is eliminated earlier in resistant mice. Intracerebral infections revealed a peculiar type of resistance of C57/bl mice especially for type 2 of HSV. HSV multiplies in the thymus at the early stage of infection and can be detected in this organ in sick mice of NMRI strain. HSV-1 and 2 can be detected in the spinal cord of C57/bl mice without sickness or death of these animals.
On the hemagglutinating and hemolytic activity of measles virus variants.
1967
The hemagglutinating (HA) and hemolytic (HL) activity of two measles virus variants, differing with regard to type of CPE and other characteristics, have been investigated.
Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal
2021
Abstract Hepatitis C virus (HCV) affects over 70 million people globally, with an estimated 399 000 HCV‐related deaths in 2016. The World Health Organization (WHO) has set a goal to eliminate HCV by 2030. Despite the availability of direct‐acting antivirals—highly effective and well‐tolerated therapies for HCV—many patients infected with HCV in Germany have not initiated treatment, including a majority of those who are aware of their positive diagnosis. Barriers to screening, diagnosis, and treatment are major factors taking many countries off track for HCV elimination by 2030. Identifying country‐specific barriers and challenges, particularly in at‐risk populations such as people who injec…
Hepatitis C virus infection and global kidney health: the consensus proceedings of the International Federation of Kidney Foundations
2020
Hepatitis C virus (HCV) infection is an important cause of major morbidities including chronic liver disease, liver cancer, and acute kidney injury (AKI) as well as chronic kidney disease (CKD). HCV can affect kidney health; among CKD and AKI patients with HCV infection, the clinical outcomes are worse. The prevalence of HCV infection is exceptionally high among dialysis and kidney transplant patients throughout the globe. It is estimated that 5% to 25% or more of dialysis dependent patients are affected by chronic HCV, based on the region of the world. Almost half of all deaths in CKD patients, including HCV-infected patients, are due to cardiovascular disease, and HCV infected patients ha…
Cutaneous Adverse Reactions to Highly Antiretroviral Therapy in HIV-Positive Patients
2013
Adverse drug reactions to highly antiretroviral therapy (HAART) are major obstacles in its success. Although overall mortality from HIV has dramatically declined owing to HAART, these antiretroviral regimens have been associated with a wide spectrum of severe cutaneous reactions. The severity of cutaneous adverse reactions varies greatly, and some may be difficult to manage. To optimize adherence and efficacy of antiretroviral treatment, clinicians must focus on preventing adverse effects whenever possible, and distinguish those that are self-limited from those that are potentially serious. This paper presents the case of a serious cutaneous adverse reaction to Atripla in a HIV-positive 50-…
Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective
2012
Until very recently, treatment for chronic hepatitis C virus (HCV) infection has been based on the combination of two non-viral specific drugs: pegylated interferon-α and ribavirin, which is effective in, overall, about 40%-50% of cases. To improve the response to treatment, novel drugs have been designed to specifically block viral proteins. Multiple compounds are under development, and the approval for clinical use of the first of such direct-acting antivirals in 2011 (Telaprevir and Boceprevir), represents a milestone in HCV treatment. HCV therapeutics is entering a new expanding era, and a highly-effective cure is envisioned for the first time since the discovery of the virus in 1989. H…
The relevance for Public Health of the mid-term and interim analyses of seasonal influenza vaccination effectiveness
2019
Worldwide, influenza is commonly recognized as a respiratory virus that causes a high number of deaths every year, especially among elderly adults and people with chronic illnesses. In order to reduce morbidity and mortality, many countries have implemented, in the last decades, universal influenza vaccination programs with special attention on groups at increased risk of developing the disease, such as pregnant women, children aged 6–59 months, elderly adults and individuals with specific chronic medical conditions. In real-world conditions, observational (nonrandomized) studies on vaccine effectiveness (VE) could measure,the risk reduction of contracting a disease and are considered the g…